Cardiac changes around the final menstrual period

Article

An analysis of data from SWAN underscores the importance of monitoring women going through menopause for cardiovascular disease (CVD) risk factors.

Heart

©violetkaipa - stock.adobe.com

An analysis of data from the Study of Women’s Health Around the Nation (SWAN) underscores the importance of monitoring women going through menopause for cardiovascular disease (CVD) risk factors. The findings, which focus on arterial stiffness within 1 year of the final menstrual period (FMP), point to a particular need to counsel black women early about lifestyle modifications to improve heart health.

Published in Arteriosclerosis, Thrombosis, and Vascular Biology, the research was an evaluation of 339 SWAN participants who had ≤ 2 carotid-femoral pulse-wave velocity (cfPWV) exams over a mean±SD of 2.3±5 years of follow-up. (cfPWV is a measure of aortic wall stiffness.) The aim was to determine whether and when women experience changes in arterial stiffness relative to their FMP and if those changes differ between black and white women. 

Methods
The authors estimated annual percentage changes in cfPWV in three time segments relative to FMP: more than 1 year before FMP (segment 1), within 1 year of FMP (segment 2), and more than 1 year after FMP (segment 3). Piecewise linear mixed-effects models were used to estimate and compare annual changes in cfPWV among time segments. 

At baseline, women were 51.1±2.8 years of age and 36% of them were black. They completed self- and interviewer-administered questionnaires on sociodemographic and lifestyle factors and medical history at visits that coincided with their cfPWV exams. Physical activity, menopause status, and use of medications for cholesterol, blood pressure and diabetes also were self-reported and assessed. 

Findings
The authors found that annual percentage change (95% confidence interval [CI]) in cfPWV varied by time segment: 0.9% (-0.6% to 2.3%) for segment 1 FMP, 7.5% (4.1% to 11.1%) for segment 2 and -1.0% (-2.8% to 0.8%) for segment 3. Annual percentage change in cfPWV for segment 1 was significantly greater than for segments 2 and 3; P< 0.05 for both comparisons. Adjusting for concurrent CVD risk factors explained part of the change estimate but did not eliminate the difference. 

Only in segment 1 did race modify the rate of change in cfPWV, with black women showing an annual increase of 2.0% versus 0.6% for white women (P= 0.04 for racial difference). Only black women had a statistically significant increase in cfPWV within segment 1.

 

Conclusions
The authors noted that the significant increases in central arterial stiffness seen in the 1-year period around FMP were independent of aging, midlife CVD risk factors, estradiol and follicle stimulating hormone levels. “Our results,” the said, “are consistent with previous findings showing significant vascular structural changes and CVD risk factors worsening around the time of FMP. Collectively, our findings underscore the importance of frequent and timely monitoring of CVD risk factors and stressing more intensive lifestyle modifications in women transitioning through menopause.”  

Recent Videos
March of Dimes 2024 Report highlights preterm birth crisis | Image Credit: marchofdimes.org
Understanding and managing postpartum hemorrhage: Insights from Kameelah Phillips, MD | Image Credit: callawomenshealth.com
Rossella Nappi, MD, discusses benefits of fezolinetant against vasomotor symptoms | Image Credit: imsociety.org
How AI is revolutionizing breast cancer detection | Image Credit: simonmed.com
Understanding cardiovascular risk factors in women | Image Credit: cedars-sinai.org.
Christie Hilton, DO, discusses breast cancer management | Image Credit: findcare.ahn.org
Updated FLUBLOK label expands influenza vaccine options for pregnant women | Image Credit: mass-vaccination-resources.org
Sheryl Kingsberg, PhD: Psychedelic RE104 for postpartum depression
Mammograms may reveal hidden cardiovascular risks, study finds | Image Credit: providers.ucsd.edu
Related Content
© 2024 MJH Life Sciences

All rights reserved.